A common blood pressure drug is showing new promise to help treat and cure type 1 diabetes.
Read More »Managing Editor, Diabetes in Control
FDA Warns of Increased Heart-Failure Risk With Two New Diabetes Drugs
New alert issued for type 2 patients taking saxagliptin (Onglyza, AstraZeneca) and alogliptin (Nesina, Takeda).
Read More »Prevalence of Diabetic Nephropathy In Pediatric Patients
Marked increase found at age 12.
Read More »Prediabetes Patients Improve Fasting Glucose with Zinc
Six-month regimen of 30 mg zinc sulfate once daily found effective compared with those on placebo, according to study.
Read More »Effect of Leisure-time Physical Activity on HbA1c in Type 2 Diabetes
Are some leisure-time activities more helpful than others in lowering blood glucose?
Read More »Team Novo Nordisk’s Peron Helps Inspire Athletes with Diabetes
Team Novo Nordisk’s Italian sprinter, Andrea Peron, rode in the main breakaway at the 107th edition of Milan-San Remo for the second consecutive year. The 293-kilometer race is the longest one-day race in the world.
Read More »Prevalence of Diabetes in U.S. Adults from 1988-2012
Overall prevalence of diabetes may have increased, but undiagnosed diabetes may be declining.
Read More »Reduction in Blood Glucose through SGLT-2 Therapy Does Not Prevent Diabetic Bone Disease
Take bone density, history of osteoporosis into consideration when prescribing.
Read More »Severe Hypoglycemia in Type 2 Diabetes Linked to Progression of Coronary Artery Disease
Patients treated with standard therapy for blood glucose control show link between serious hypoglycemia and CAC progression, increasing risk of heart attack and stroke.
Read More »Battle of the GLP-1 Agonists: Liraglutide vs. Exenatide
Liraglutide may help type 2 diabetes patients achieve tighter glycemic control with fewer side effects than exenatide.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.